RETRACTION: Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer (Retraction of Vol 2022, art no 4632453, 2022)

被引：0
|
作者：
Xu, Y.
BioMed Res Int
机构：
来源：
BIOMED RESEARCH INTERNATIONAL | 2023年 / 2023卷
关键词：
D O I：
10.1155/2023/9870382
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页数：1
相关论文
共 14 条
  • [1] RETRACTED: Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer (Retracted Article)
    Xu, Yingkun
    Shen, Meiying
    Peng, Yang
    Liu, Li
    Tang, Lingfeng
    Yang, Ting
    Pu, Dongyao
    Tan, Wenhao
    Zhang, Wenjie
    Liu, Shengchun
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [2] RETRACTION: FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma (Retraction of Vol 2022, art no 5160748, 2022)
    Wu, S.
    Liang, Y.
    Zang, Q.
    APPLIED BIONICS AND BIOMECHANICS, 2023, 2023
  • [3] A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors
    Fang, Hui
    Sheng, Shuyan
    Chen, Bangjie
    Wang, Jianpeng
    Mao, Deshen
    Han, Yanxun
    Liu, Yuchen
    Wang, Xinyi
    Gui, Siyu
    Zhang, Tongyuan
    Zhang, Lizhi
    Li, Conghan
    Hu, Xinyang
    Deng, Wanyu
    Liu, Xin
    Xu, Honghai
    Xu, Wentao
    Wang, Xingyu
    Liu, Rongqiang
    Kong, Weihao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] RETRACTION: Systematic pan-cancer analysis identifies transmembrane protein 158 as a potential therapeutic, prognostic and immunological biomarker (Retraction of Vol 23, art no 105, 2023)
    Li, Jiayi
    Hou, Haiguang
    Sun, Jinhao
    Ding, Zhaoxi
    Xu, Yingkun
    Li, Guibao
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2024, 24 (03)
  • [5] Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy (vol 14, 5344, 2022)
    Zheng, Haosheng
    Long, Guojie
    Zheng, Yuzhen
    Yang, Xingping
    Cai, Weijie
    He, Shiyun
    Qin, Xianyu
    Liao, Hongying
    CANCERS, 2023, 15 (03)
  • [6] RETRACTION: The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis (Retraction of Vol 2022, art no 2731744, 2022)
    Fan, Z.
    APPLIED BIONICS AND BIOMECHANICS, 2023, 2023
  • [7] RETRACTION: circ-RANGAP1/MicroRNA-542-3p/Myosin Regulatory Light Chain Interacting Protein Axis Modulates the Osteosarcoma Cell Progression (Retraction of Vol 2022, art no 4247670, 2022)
    Sheng, J.
    Liu, J.
    Du, J.
    Wang, Y.
    APPLIED BIONICS AND BIOMECHANICS, 2023, 2023
  • [8] RETRACTION: MicroRNA-671-5p inhibits cell proliferation, migration and invasion in non-small cell lung cancer by targeting MFAP3L (Retraction of Vol 25, art no 30, 2022)
    Ye, Junhui
    Luo, Wujun
    Luo, Lingling
    Zhai, Limin
    Huang, Pingping
    MOLECULAR MEDICINE REPORTS, 2024, 29 (06)
  • [9] RETRACTION: MiR-483 Promotes Colorectal Cancer Cell Biological Progression by Directly Targeting NDRG2 through Regulation of the PI3K/AKT Signaling Pathway and Epithelial-to-Mesenchymal Transition (Retraction of Vol 2022, art no 4574027, 2022)
    Journal Healthcare Engn, Journal of Healthcare
    JOURNAL OF HEALTHCARE ENGINEERING, 2022, 2022
  • [10] RETRACTION: Circ_0017639 facilitates proliferative, migratory, and invasive potential of non-small cell lung cancer (NSCLC) cells via PI3K/AKT signaling pathway (vol 13, pg 1590, 2022) (Retraction of Vol 13, Pg 1590, 2022)
    Zhang, Hong-Bo
    Qiu, Xiang-Ming
    Zhang, Yi-Chao
    Huang, Ting-Ting
    Zuo, Zhan-Jie
    Zhang, Tao
    BIOENGINEERED, 2024, 15 (01)
12